Survey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general public
Survey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general public |
| [08-October-2024] |
TUCSON, Ariz., Oct. 8, 2024 /PRNewswire/ -- GWI research commissioned by Roche (SIX: RO, ROG; OTCQX: RHHBY) and carried out across 12 countries in Latin America and Europe has revealed that half of those polled have either limited or no awareness of the important role human papillomavirus (HPV) plays in cervical cancer.1
HPV is a common virus transmitted through sexual contact and is the primary cause of cervical cancer, responsible for over 99% of cases.2 Every year, more than 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die, with nine in every ten of these women living in low-resource countries.3 However, 93% of cervical cancers could be prevented entirely through appropriate screening and HPV vaccination.4 The research also demonstrated that with screening rates varying between regions, significant barriers continue to exist that are preventing women from seeking testing.1 Respondents in all countries, including both developed and developing nations, reported that concerns about the testing procedure being painful were common (up to 63% in some countries), as well as a sense of discomfort about discussing their sexual history or sexuality with a healthcare provider (up to 57% in some countries).1 "Thousands of women are needlessly dying from cervical cancer every year. This survey highlights some of the most important barriers to screening, as well as the opportunities we have to prevent disease and improve women's health," said Joanna Sickler, Vice-President, Health Policy and External Affairs at Roche Diagnostics. "With many women reporting being open to new screening tools like self collection, it has never been more important that communities, health systems, governments and innovators come together to seize this opportunity, and provide the early detection and treatment needed to avoid so many preventable deaths." The WHO is focused on accelerating the elimination of cervical cancer globally,2 with its latest guidelines recommending HPV DNA testing as primary screening for all women.5 Its strategy seeks to ensure that by 2030, 90% of girls are fully vaccinated against HPV by age 15. It also aims for 70% of women to have been screened using a high-performance test by age 35, and again by age 45, with 90% of those eligible linked to treatment. This, along with vaccination against HPV, could prevent more than 62 million deaths in the next 100 years.2 More than 50%of new cervical cancers occur in women who have never been screened, or have not been screened in the previous five years of their lives.6 Many factors can contribute to individuals not participating in cervical cancer screening programs, such as access to healthcare, social and economic barriers, history of traumatic experience, cultural concerns and embarrassment. The many barriers preventing women from seeking HPV screening could explain the widespread interest in self-testing revealed by the survey. In European countries, where testing is more routinely available, 57% of women were interested in the opportunity to collect their own samples for testing. This figure rose to 77% in Latin American countries, where routine screening is less readily available because of a lack of infrastructure and available appointment means. This discrepancy was also reflected in healthcare professional-reported results, which showed 72% of healthcare professionals and government workers in Latin American countries agree their country needs a self-collection programme, compared to 48% in Europe. Susana Wong, Patient Advocate and Director of Lazo Rosado, Perú, is working to expand access to HPV testing in her country. She notes: "We know very well how to prevent and treat cervical cancer. Now, with HPV molecular tests and vaccination, there really is hope to eliminate this disease. This test gives you the opportunity to live and to live well with your family. It can help women to empower themselves as to their health." Men demonstrated even lower levels of awareness compared to women, particularly in Europe. While 55% to 76% of men in Latin America reported some understanding of HPV, only 35% to 51% of men in Europe had any understanding of HPV at all. The lower awareness among men highlights the need for educational initiatives to include men, given their potential role in the transmission and prevention of HPV. "This survey highlights both the challenges ahead and the significant opportunities we have to advance HPV prevention," Sickler said. "By enhancing public education about HPV risks and reimagining how we deliver care, we can drive higher screening rates and make meaningful progress in combating cervical cancer." Fighting cervical cancer In September 2024, Roche officially joined the Global HPV Consortium. This presents an opportunity to collaborate globally, aligning our efforts with other organisations to advance cervical cancer prevention efforts and raise the prominence of early screening and timely detection using high-performance HPV-DNA tests. Roche already partners with health systems and governments in more than 55 countries to support their cervical cancer screening programs with the cobas® HPV test. As a result of these collaborations, more women have been accessing HPV molecular testing. For example, since 2021, when Roche and the Perúvian Ministry of Health started working together, along with other government organisations and patient advocates, more than 300,000 unscreened or underscreened women, some in remote areas of the Amazon rainforest, have been tested for HPV using Roche's self-collection solution as the primary strategy to expand access. The cobas® HPV test is also part of the Roche Global Access Program, which aims to improve access to cost-effective resources, implement scale-up programs, and contribute to the elimination of diseases in the regions with the greatest need. About the Roche HPV Health Understanding Survey Conducted in Q1 2024, the HPV Health Understanding Survey was carried out by GWI on behalf of Roche. Surveying 8,703 men and women across 12 countries, it was designed to assess the general population's awareness of HPV and its role in the development of cervical cancer, as well as access to cervical health screening and barriers to care. It also measured perceptions among 2,585 healthcare professionals (HCPs) and government professionals of HPV testing availability in their own market. Survey participants:
About the Global Access Program The continual expansion of test offerings highlights Roche's commitment to eliminating cervical cancer and other high-burden infectious diseases for patients living in resource-constrained settings with limited access. Any laboratory that implements a Roche instrument system gains the ability to scale up testing across multiple disease areas, thus improving cost and resource efficiency. An integrated approach supports national programs focused on increasing access to diagnostic testing, to help manage or reduce the impact of preventable disease for patients. About the Roche Diagnostics Cervical Cancer Portfolio The HPV self-collection solution is approved for use with Roche's cobas HPV test. The cobas HPV test runs on the cobas 4800 and the fully automated cobas 5800/6800/8800 Systems, which offers the fastest time to results, providing up to 96 results in about three hours, and 384 results for the cobas 6800 System and 1,056 results for the cobas 8800 System in an eight hour shift. The portfolio also includes CINtec PLUS Cytology, the only FDA-approved dual-stain product and CINtec® Histology, the only FDA-cleared p16 biomarker technology that can help pathologists confirm the presence of pre-cancerous cervical lesions. The IMPACT trial design, used to validate the clinical benefits of the Roche cervical cancer portfolio, had representation from diverse patient segments, including 21 percent Black, 24 percent Hispanic-Latino and 0.3 percent American Indian or Alaskan Native participants8 . This diversity was critical to accurately assess the performance of dual stain in patient populations with higher incident rates of HPV. Learn more now: http://diagnostics.roche.com. About Roche In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com References Roche Media Relations Jo Lynn Garing Amberly Peterson Kathryn Ager
SOURCE Roche | ||||||||||||||||||||||||||||
Company Codes: Swiss:ROG, OTC-PINK:RHHBY, Swiss:RO, NYSE:ROG, OTC-BB:RHHBY, OTC-QX:RHHBY, OtherOTC:RHHBY |
View original content to download multimedia:
